stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Total debt
Recursion Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $9.6M, down 49.7% from $19.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $93.0K. Over the past ten years it has ranged from $536.0K (fiscal 2022) to $45.0M (fiscal 2022); the current reading is higher than 36% of that period. Recursion Pharmaceuticals, Inc. ranks 501st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $9.6M | (49.72%) |
| FY2024 | $19.0M | 1,627.70% |
| FY2023 | $1.1M | 105.41% |
| FY2022 | $536.0K | (98.81%) |
| FY2022 | $45.0M | 7,002.05% |
| FY2021 | $633.0K | (93.65%) |
| FY2021 | $10.0M | (12.63%) |
| FY2020 | $11.4M | (19.18%) |
| FY2020 | $14.1M | 13.72% |
| FY2019 | $12.4M | (23.20%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $93.0K | (98.04%) |
| Jun 2026 | $4.8M | (33.81%) |
| Mar 2026 | $7.2M | (24.92%) |
| Dec 2025 | $9.6M | (19.64%) |
| 21 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| VCEL Vericel Corporation compare | $85.1M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| CLDX Celldex Therapeutics, Inc. compare | $1.2M |
| PHVS Pharvaris N.V. compare | $559.6K |
| NAMS NewAmsterdam Pharma Company N.V. compare | $94.9K |
| RXRX Recursion Pharmaceuticals, Inc. | $93.0K |
| MBX MBX Biosciences, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement